An official website of the United States government
Home
Name
Bosutinib
Alternate Names
Bosulif
SKI 606
SKI-606
Abbreviations
BOS
Category
Chemotherapy
Subcategory
Tyrosine kinase inhibitor
NSC Number
None
Primary Site
CML
Histology
None
Remarks
9/26/2023 The FDA approved bosutinib (Bosulif) for pediatric patients 1 year of age and older with chronic phase (CP) Ph+ chronic myelogenous leukemia (CML) that is newly diagnosed (ND) or resistant or intolerant (R/I) to prior therapy.
12/19/2017: FDA granted accelerated approval to bosutinib for treatment of patients with newly diagnosed chronic-phase Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia (CML).
9/4/2012: Bosulif received FDA approval as an Orphan Drug to treat CML
12/19/2017: FDA granted accelerated approval to bosutinib for treatment of patients with newly diagnosed chronic-phase Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia (CML).
9/4/2012: Bosulif received FDA approval as an Orphan Drug to treat CML
Coding
This drug should be coded
